About This Webinar
The enzyme-linked immunosorbent spot (ELISpot) assay is one of the most commonly used methods to measure antigen-specific T cells in both mice and humans. Some of the primary reasons for the popularity of the method are that ELISpot is highly quantitative, can measure a broad range of magnitudes of response and is capable of assessing critical cellular immune-related activities Furthermore, ELISpot is adaptable not only to the evaluation of a variety of T-cell functions, but also to B cells and innate immune cells. It is no wonder that ELISpot has evolved from a research tool to a clinical assay. Through this webinar we are trying to highlighting Elispot technique being used in immune monitoring.
Assistant Professor (Technical manager), Interactive Research School for Health Affairs (IRSHA)
ICMR-National Institute of Virology, Pune
Senior Manager and Head of Viral Vaccine Research and Development at Zydus Cadila Healthcare Ltd
Formerly Executive Director
Indoor Biotechnologies India Private Limited, Bangalore
Scientific research professional with a broad set of analytical and technical skills required for viral immunology research. Expertise in Flow cytometry with 14 years of experience. Well versed with GCLP compliance and Laboratory quality control aspects.
Scientist ‘E’, Pathogenesis of Hepatitis, chikungunya, dengue viruses, assessment of vaccine induced immune response, providing diagnosis and involvement in various viral outbreaks, Epidemiology of hepatitis viruses, Teaching post graduate students, Guiding Ph.D students.
Dr. Ayan Dey is Senior Manager and Head of Viral Vaccine Research and Development at Zydus Cadila Healthcare Ltd.
Dr. Dey have over 15.0+ years of experience in academia, industry and international organization. His expertise includes Vaccines discovery, upstream and downstream process development as per cGMP requirement, immunoassays and analytical method development and validation in accordance with GLP and GCP requirements.
Dr. Dey is trained as a microbiologist with specialization in immunology and infectious disease research. He has done his Ph.D on the "development of chimeric DNA vaccine against Leishmaniasis and Tuberculosis", from All India Institute of Medical Sciences, New Delhi, India. Subsequently he joined Panacea Biotec Ltd as Research and Development Scientist. In 2010, he moved to South Korea, joining International Vaccine Scientist (IVI) as Scientist. His role was to support the institute research activities in Laboratory Science Division by developing vaccine candidate for neglected diseases and further assessing the nature and intensity of immune responses induced by candidate vaccines, especially in young children from developing countries. In 2019 he return back to India and joined Zydus Cadila Healthcare Ltd. Dr. Dey’s have led several vaccine research project funded by Gates Foundation, Korean National research Foundation, Department of Biotechnology, Government of India.
Dr. Dey’s achievements includes publication of several article in Peer Reviewed Journal, Patent and presentation in various international and national symposium. He also received travel award from Gates Foundation twice for research presentation.
Dr. Sivasankar Baalasubramanian (known as Shiv) is a scientist turned entrepreneur with 19 years of research experience in the areas of infectious diseases and cancer. Shiv was formerly the executive director of Indoor Biotechnologies India Private Limited which he co-founded and excited recently. Currently he is on the path to launch his own venture.
Shiv's research focuses on understanding molecular and cellular immunology in the areas of infectious diseases and cancer. Shiv through his research demonstrated that a functional complement system was critical for survival during influenza infection. Demonstrated a unique and previously unknown role for CD59 in augmenting T cell immunity. Furthermore, developed therapeutic molecules, and tested them in preclinical models, and generated several monoclonal antibodies that were commercialized jointly with industry partners. More recently, Shiv has been working with vaccine companies to understand vaccine efficacy in mediating cell mediated immunity to COVID-19.
Shiv received his PhD from the All-India Institute of Medical Sciences (AIIMS), New Delhi and was subsequently awarded the Wellcome Trust International Travelling Fellowship, which enabled him to work at School of Medicine, Cardiff University, UK. Prior to return to India to set up Indoor Biotechnologies, he worked as a Principal Investigator at the Singapore Institute of Clinical Sciences.